Literature DB >> 1826619

Characterization in rat aorta of the binding sites responsible for blockade of noradrenaline-evoked calcium entry by nisoldipine.

N Morel1, T Godfraind.   

Abstract

1. The effectiveness of the calcium antagonist, 1,4-dihydropyridine nisoldipine, as an inhibitor of contraction and 45Ca entry evoked by noradrenaline in rat aorta has been investigated and correlated with binding characteristics in intact artery. 2. Contractions evoked by noradrenaline were concentration-dependently depressed by nisoldipine (0.3-300 nM). About 60% of the response was resistant to inhibition, while KCl-induced contractions could be completely blocked. Noradrenaline-induced contractions were also less sensitive to nisoldipine inhibition than were KCl-induced contractions. 3. Preincubation of the aorta with nisoldipine in high KCl depolarizing solution increased the inhibition of the contraction evoked by a short application of noradrenaline or KCl to a similar extent. 4. The inhibition by nisoldipine of 45Ca influx evoked either by KCl depolarizing solution or by noradrenaline correlated well with the inhibition of the contractile responses. However, while KCl-stimulated 45Ca influx was totally abolished by nisoldipine (300 nM), 38% of the noradrenaline-stimulated 45Ca influx was resistant to inhibition by nisoldipine (300 nM). 5. The study of [3H]-(+)-PN 200-10 ([3H]-(+)-isradipine) binding in intact aorta showed the presence of a homogeneous population of specific binding sites. KD values were dependent on the KCl concentration in the bath while Bmax was unaffected. Binding of [3H]-(+)-isradipine was also increased in tissue exposed to noradrenaline; in the presence of 10(-5) M noradrenaline, binding parameters of [3H]-(+)-isradipine were close to the values obtained in aorta bathed in 20 mM KCl solution. 6. Displacement of [3H]-(+)-isradipine specific binding by nisoldipine was determined in segments of mesenteric artery and of aorta. The potency of nisoldipine was dependent on the incubation conditions applied to the vessel, as follows: KCl (100 mM) depolarizing solution greater than noradrenaline (10(-5) M) = KCl (25 mM) solution greater than physiological solution. The Ki value measured in aorta exposed to noradrenaline (10(-5) M) was close to the IC50 value of nisoldipine on the noradrenaline-evoked contraction. 7. The membrane potential value of rat aorta was estimated by the distribution of [3H]-tetraphenylphosphonium bromide ([3H]-TPP+), [3H]-TPP+ uptake concentration-dependently decreased when the KCl concentration in the bath was increased from 5.9 to 130 mM. Noradrenaline also concentration-dependently decreased [3H]-TPP+ uptake; the maximum effect (1-10 microns noradrenaline) was comparable in amplitude to the effect of 25 mM KCl solution. 8. It is concluded that in rat aorta, noradrenaline activates voltage-operated calcium channels that contain the specific, voltage-sensitive binding sites for calcium antagonistic dihydropyridines. The existence of a fraction of noradrenaline-stimulated '"Ca entry that is resistant to nisoldipine blockade suggests that another Ca2 + entry pathway is also opened by the agonist.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1826619      PMCID: PMC1918032          DOI: 10.1111/j.1476-5381.1991.tb12196.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  45 in total

1.  Prolonged depolarization increases the pharmacological effect of dihydropyridines and their binding affinity for calcium channels of vascular smooth muscle.

Authors:  N Morel; T Godfraind
Journal:  J Pharmacol Exp Ther       Date:  1987-11       Impact factor: 4.030

2.  EDRF and cyclic GMP control gating of receptor-operated calcium channels in vascular smooth muscle.

Authors:  T Godfraind
Journal:  Eur J Pharmacol       Date:  1986-07-31       Impact factor: 4.432

3.  Pharmacologic relevance of dihydropyridine binding sites in membranes from rat aorta: kinetic and equilibrium studies.

Authors:  M Wibo; L DeRoth; T Godfraind
Journal:  Circ Res       Date:  1988-01       Impact factor: 17.367

Review 4.  Alpha 1-adrenergic receptor subtypes, inositol phosphates, and sources of cell Ca2+.

Authors:  K P Minneman
Journal:  Pharmacol Rev       Date:  1988-06       Impact factor: 25.468

Review 5.  Are junction potentials essential? Dual mechanism of smooth muscle cell activation by transmitter released from autonomic nerves.

Authors:  T B Bolton; W A Large
Journal:  Q J Exp Physiol       Date:  1986-01

6.  Enhanced responsiveness of rat isolated aorta to clonidine after removal of the endothelial cells.

Authors:  C Eglème; T Godfraind; R C Miller
Journal:  Br J Pharmacol       Date:  1984-01       Impact factor: 8.739

7.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

8.  Endothelium-dependent effects of acetylcholine in rat aorta: a comparison with sodium nitroprusside and cromakalim.

Authors:  S G Taylor; J S Southerton; A H Weston; J R Baker
Journal:  Br J Pharmacol       Date:  1988-07       Impact factor: 8.739

9.  Studies on Ca channels in intact cardiac cells: voltage-dependent effects and cooperative interactions of dihydropyridine enantiomers.

Authors:  S Kokubun; B Prod'hom; C Becker; H Porzig; H Reuter
Journal:  Mol Pharmacol       Date:  1986-12       Impact factor: 4.436

10.  Some electrical properties of the endothelium-dependent hyperpolarization recorded from rat arterial smooth muscle cells.

Authors:  G Chen; H Suzuki
Journal:  J Physiol       Date:  1989-03       Impact factor: 5.182

View more
  12 in total

1.  Endothelial modulation of alpha 1-adrenoceptor contractile responses in the tail artery of spontaneously hypertensive rats.

Authors:  A Tabernero; J Giraldo; N M Vivas; A Badia; E Vila
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

2.  Action of a NO donor on the excitation-contraction pathway activated by noradrenaline in rat superior mesenteric artery.

Authors:  P Ghisdal; J P Gomez; N Morel
Journal:  J Physiol       Date:  2000-01-01       Impact factor: 5.182

3.  Sources of calcium and alpha 1-adrenoceptor-mediated contraction in rat tail artery.

Authors:  A Tabernero; N M Vivas; E Vila
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

4.  Characterisation of marrubenol, a diterpene extracted from Marrubium vulgare, as an L-type calcium channel blocker.

Authors:  Sanae El-Bardai; Maurice Wibo; Marie-Christine Hamaide; Badiaa Lyoussi; Joelle Quetin-Leclercq; Nicole Morel
Journal:  Br J Pharmacol       Date:  2003-11-03       Impact factor: 8.739

5.  Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.

Authors:  S Salomone; T Godfraind
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

Review 6.  Nisoldipine coat-core. A review of its pharmacology and therapeutic efficacy in hypertension.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1996-08       Impact factor: 9.546

7.  Rho-dependent kinase is involved in agonist-activated calcium entry in rat arteries.

Authors:  Philippe Ghisdal; Greet Vandenberg; Nicole Morel
Journal:  J Physiol       Date:  2003-07-09       Impact factor: 5.182

8.  The effect of omega-conotoxin GVIA on synaptic transmission within the nucleus accumbens and hippocampus of the rat in vitro.

Authors:  A L Horne; J A Kemp
Journal:  Br J Pharmacol       Date:  1991-07       Impact factor: 8.739

Review 9.  Cardioselectivity of calcium antagonists.

Authors:  T Godfraind
Journal:  Cardiovasc Drugs Ther       Date:  1994-05       Impact factor: 3.727

10.  Evidence that depletion of internal calcium stores sensitive to noradrenaline elicits a contractile response dependent on extracellular calcium in rat aorta.

Authors:  M A Noguera; M P D'Ocon
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.